US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

1.31

+0.220020.00%

Volume:199.08K

Turnover:249.03K

Market Cap:32.90M

PE:-0.62

High:1.37

Open:1.20

Low:1.20

Close:1.10

52wk High:8.94

52wk Low:0.9174

Shares:25.11M

Float Shares:18.57M

Volume Ratio:39.83

T/O Rate:1.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.1105

EPS(LYR):-1.1597

ROE:-2660.81%

ROA:-170.69%

PB:-36.15

PE(LYR):-1.13

Loading ...

Overview Company News Filings

Medicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg

Medicus Pharma Receives FDA Clearance to Proceed with Teverelix Phase 2b Study

Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel

BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital

BUZZ-Medicus Pharma gains after cutting royalty payment to Teverelix

Medicus Pharma : Amendment Does Not Alter Scope of License, Underlying Intellectual Property, or Respective Development Responsibilities of Parties

THOMSON REUTERS

Medicus Pharma : Amendment Reduces & Simplifies Royalty Structure on Teverelix From About 4% to 2%

THOMSON REUTERS

Antev Ltd. Secures Reduced Royalty Deal to Boost Teverelix Economic Profile

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Medicus Pharma announces clinical data on Teverelix

Medicus Pharma Completes Phase 2 Enrollment for SkinJect Basal Cell Carcinoma Study

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. to Present at Biotech Showcase 2026

ADVISORY-Dated alerts on Medicus Pharma withdrawn

Medicus Pharma Ltd - Entered Into Sales Agreement With Maxim and Yorkville - SEC Filing

THOMSON REUTERS

Medicus Pharma Ltd - May Offer and Sell Common Shares up to $15,349,674 - SEC Filing

THOMSON REUTERS

Medicus Pharma Ltd - to Offer Shares up to $15.35 Mln - SEC Filing

THOMSON REUTERS

Medicus Pharma Ltd - on Dec 29, Entered Equity Distribution Agreement With Maxim Group & Yorkville Securities - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":1.32,"timestamp":1771425145723,"preClose":1.1,"halted":0,"volume":198845,"delay":0,"changeRate":0.19999999999999996,"floatShares":18570200,"shares":25114144,"eps":-2.1105,"marketStatus":"Trading","change":0.22,"latestTime":"02-18 09:32:26 EST","open":1.2,"high":1.3685,"low":1.195,"amount":249028.7256045,"amplitude":0.157727,"askPrice":1.33,"askSize":777,"bidPrice":1.25,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-2.1105,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.1999,"preClose":1.1,"latestTime":"09:29 EST","volume":58652,"amount":69576.51565480001,"timestamp":1771424998310,"change":0.0999,"changeRate":0.090818,"amplitude":0.044545},"postHourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.1,"latestTime":"19:51 EST","volume":15731,"amount":17919.5476,"timestamp":1771375904621,"change":0.02,"changeRate":0.018182,"amplitude":0.045455},"volumeRatio":39.780432},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":18570200,"roa":"-170.69%","roe":"-2660.81%","lyrEps":-1.159715,"volumeRatio":39.826446,"shares":25114144,"dividePrice":0,"high":1.3685,"amplitude":0.157727,"preClose":1.1,"low":1.195,"week52Low":0.9174,"pbRate":"-36.15","week52High":8.94,"institutionHeld":0,"latestPrice":1.31,"committee":0.440403,"eps":-2.1105,"divideRate":0,"volume":199075,"delay":0,"ttmEps":-2.1105,"open":1.2,"prevYearClose":1.53,"prevWeekClose":1.06,"prevMonthClose":1.19,"prevQuarterClose":1.53,"fiveDayClose":1.03,"twentyDayClose":1.37,"sixtyDayClose":2.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post Market","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744866000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-02-17","current":-0.521204,"percent":0.975,"low":-3.23298,"twenty":-2.85149,"median":-1.907346,"eighty":-0.964331,"high":-0.678935,"avg":-1.868466,"sd":0.870273,"marketCap":27082981},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-17","current":-0.757549,"twenty":-2.85149,"median":-1.907346,"eighty":-0.964331,"marketCap":27082981}],"updateTime":1771422438664},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610925119","title":"Medicus Pharma CEO Highlights AI-Driven Drug Development on Bloomberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610925119?lang=en_us&edition=fundamental","pubTime":"2026-02-12 20:30","pubTimestamp":1770899432,"startTime":"0","endTime":"0","summary":"Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma Ltd. , appeared on Bloomberg World for a live interview with anchor Matt Miller. During the discussion, Dr. Bokhari outlined the company's AI-driven approach to accelerating drug development and highlighted how Medicus Pharma's leadership has committed nearly $14 million of personal capital at $4 per share to advance its pipeline. He expressed optimism that upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, would change investor perception and unlock significant value. The interview also addressed the challenges facing biotech stocks and the transformative potential of artificial intelligence in innovative therapy development. Click here to watch the full interview.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL30Mxvv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2610647403","title":"Medicus Pharma Receives FDA Clearance to Proceed with Teverelix Phase 2b Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2610647403","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610647403?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:30","pubTimestamp":1770726620,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has received \"study may proceed\" clearance from the U.S. Food and Drug Administration  to initiate its Phase 2b dose-optimization study of Teverelix, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer who have high cardiovascular risk. The Phase 2b open-label trial will enroll 40 patients and is designed to evaluate Teverelix as a potential treatment option for this population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on February 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL4Rfb3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4585","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4139","SG9999014039.USD","MDCX","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2605453784","title":"Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License","url":"https://stock-news.laohu8.com/highlight/detail?id=2605453784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605453784?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:07","pubTimestamp":1769123276,"startTime":"0","endTime":"0","summary":"An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma’s subsidiary Antev has amended its license agreement with UK-based m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-lowers-teverelix-royalty-burden-in-amended-lifearc-license?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-lowers-teverelix-royalty-burden-in-amended-lifearc-license?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2605385411","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel","url":"https://stock-news.laohu8.com/highlight/detail?id=2605385411","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605385411?lang=en_us&edition=fundamental","pubTime":"2026-01-23 02:42","pubTimestamp":1769107366,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, IntelEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://ref","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL6N3YN0S2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLR","WYFI","TSLA","SCCO","KMI","ADSK","ELAN","HBAN","RMBS","GGLL","NEXT","CORT","CBSH","ORI","CTSH","LRCX","VG","LTH","JPM","ACI","WINA","GGLS","NEM","MKC","CRVS","DDOG","JANX","MULL","CRSH","GLSI","INTC","CAL","BIOA","ACMR","MDCX","PSQH","ABT","TCBK","NFE","PG","GE","TDY","MUD","PSKY"],"gpt_icon":1},{"id":"2605492696","title":"BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492696","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605492696?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:11","pubTimestamp":1769091106,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Medicus Pharma, Lam Research, Applied DigitalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL6N3YN0S4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995153.HKD","PG","89988","LU2129689514.USD","LU2778985437.USD","LU0640476718.USD","ALBmain","LU0052750758.USD","LTH","CRVS","CTSH","IE00B5MMRT66.SGD","ELAN","RMBS","LU0561508036.HKD","LU0231203729.USD","HBBD.SI","CORT","VG","89888","LU0516423174.USD","MDCX","LRCX","JANX","KMI","BIOA","BMY","LU0315178854.USD","GLSI","WYFI","BTBT","LU0545039389.USD","LU3063872942.SGD","GB00BDT5M118.USD","MULL","APLD","MUD","CAL","ABT","BK1249","LU2129689605.HKD","GE","HBAN","LU2152927971.USD"],"gpt_icon":1},{"id":"2605499443","title":"BUZZ-Medicus Pharma gains after cutting royalty payment to Teverelix","url":"https://stock-news.laohu8.com/highlight/detail?id=2605499443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605499443?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:03","pubTimestamp":1769087019,"startTime":"0","endTime":"0","summary":"BUZZ-Medicus Pharma gains after cutting royalty payment to Teverelix** Shares of drug developer Medicus Pharma MDCX.O rise 12% to $1.49 premarket ** Co says it has cut royalty payments on investigational prostate cancer drug teverelix to 2% from ~4% after amending its deal with UK research group LifeArc** Co's teverelix is being tested for advanced prostate cancer and recurring acute urinary retention, a condition where men suddenly cannot urinate** Co says early studies showed teverelix quickly lowers hormone levels key to prostate cancer treatment** MDCX plans midstage testing before seeking commercial partners; also expects early2026 data for its SkinJect skin cancer patch, per co** Shares down ~37% in 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4N3YN11A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2605965854","title":"Medicus Pharma : Amendment Does Not Alter Scope of License, Underlying Intellectual Property, or Respective Development Responsibilities of Parties","url":"https://stock-news.laohu8.com/highlight/detail?id=2605965854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605965854?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:30","pubTimestamp":1769085018,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN07L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2605049636","title":"Medicus Pharma : Amendment Reduces & Simplifies Royalty Structure on Teverelix From About 4% to 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605049636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605049636?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:30","pubTimestamp":1769085018,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN07L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2605496324","title":"Antev Ltd. Secures Reduced Royalty Deal to Boost Teverelix Economic Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2605496324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605496324?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:30","pubTimestamp":1769085016,"startTime":"0","endTime":"0","summary":"Medicus Pharma Subsidiary Antev Amends LifeArc License, Reduces Teverelix Royalty Rate to 2%. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL7B016n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014039.USD","IE00BKPKM429.USD","MDCX","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","LU0314104364.USD","BK4112","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD"],"gpt_icon":0},{"id":"2605520496","title":"Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2605520496","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605520496?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:30","pubTimestamp":1769085000,"startTime":"0","endTime":"0","summary":"Amendment reduces and simplifies royalty structure on Teverelix from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix as a first in class market product for ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/22/3223643/0/en/Medicus-Pharma-Ltd-Announces-Amendment-to-LifeArc-License-Improving-Teverelix-Long-Term-Economic-and-Development-Profile.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0786609619.USD","LU1718418525.SGD","LU0314104364.USD","LU2417539215.USD","LU0053666078.USD","LU1066053197.SGD","LU1496350171.SGD","LU2237443622.USD","BK4567","LU0077335932.USD","LU0149725797.USD","LU1066051225.USD","LU1935042488.USD","LU1066051498.USD","LU1935042991.SGD","BK4139","LU0170899867.USD","LU1935043536.SGD","MNA","LU0882574139.USD","LU2420271590.USD","APC","LU1674673428.USD","LU2456880835.USD","LU1935042215.USD","LU1778281490.HKD","LU2237443382.USD","LU1066051811.HKD","LU2237443549.SGD","MDCX","BCC","LU1674673691.USD","BK4104","LU0157215616.USD","LU1935043023.USD","LU2236285917.USD","LU2083900584.USD","91348","LU2237443978.SGD","LU1366333091.USD","LU1366192091.USD"],"gpt_icon":0},{"id":"2604118263","title":"Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2604118263","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604118263?lang=en_us&edition=fundamental","pubTime":"2026-01-20 20:30","pubTimestamp":1768912200,"startTime":"0","endTime":"0","summary":"The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221602/0/en/Medicus-Pharma-Ltd-Celebrates-One-Year-on-Nasdaq-with-Opening-Bell-Ceremony-on-January-22-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1496350171.SGD","LU2237443382.USD","LU2237443622.USD","LU2237443978.SGD","LU2417539215.USD","LU2456880835.USD","MDCX","LU0053666078.USD","LU1066051811.HKD","LU2083900584.USD","LU0786609619.USD","LU1778281490.HKD","LU1935042991.SGD","MNA","LU0882574139.USD","LU2420271590.USD","APC","LU1935042215.USD","LU1066051498.USD","LU1366333091.USD","LU0149725797.USD","LU1935043536.SGD","LU2236285917.USD","LU0077335932.USD","LU1066053197.SGD","LU0157215616.USD","LU2237443549.SGD","LU0314104364.USD","LU1718418525.SGD","LU0170899867.USD","LU1066051225.USD","LU1935042488.USD","BK4139","LU1366192091.USD","LU1674673428.USD","LU1935043023.USD","LU1674673691.USD"],"gpt_icon":0},{"id":"2602517472","title":"Medicus Pharma announces clinical data on Teverelix","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517472","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517472?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:50","pubTimestamp":1768222208,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announces that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone antagonist, have been acce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-announces-clinical-data-on-teverelix-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-announces-clinical-data-on-teverelix-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2602124465","title":"Medicus Pharma Completes Phase 2 Enrollment for SkinJect Basal Cell Carcinoma Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2602124465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602124465?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221024,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. announced that topline decision-grade data from its Phase 2 clinical trial of SkinJect, a dissolvable microneedle array platform delivering doxorubicin for the non-invasive treatment of basal cell carcinoma , is expected in the first quarter of 2026. The company has completed enrollment of 90 patients across nine U.S. sites for the SKNJCT-003 study. An End-of-Phase 2 meeting with the U.S. Food and Drug Administration  is planned for the first half of 2026. No final results have been presented yet; previously disclosed interim findings indicated greater than 60% clinical clearance in an exploratory analysis, though these results are preliminary and may not reflect the final study outcomes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLcf6kCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","MDCX","BK4585","SG9999014021.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","BK4588"],"gpt_icon":0},{"id":"2602512792","title":"Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2602512792","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602512792?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:30","pubTimestamp":1768221000,"startTime":"0","endTime":"0","summary":"The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American Association of Clinical Endocrinology (AACE) Annual meeting 2026PHILADELPHI","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216776/0/en/Medicus-Pharma-Ltd-Studies-Demonstrate-Long-Acting-Therapeutic-Approach-with-Stable-Bone-Turnover-in-Women.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCC","BK4567","LU2237443549.SGD","LU1718418525.SGD","BK4139","LU0053666078.USD","LU2237443978.SGD","LU1066051498.USD","LU1778281490.HKD","LU1935042215.USD","LU1066053197.SGD","LU1674673691.USD","LU1674673428.USD","LU0149725797.USD","LU0786609619.USD","LU2420271590.USD","MNA","LU2237443382.USD","LU0314104364.USD","LU1066051225.USD","LU0157215616.USD","BK4104","UAE","LU1366333091.USD","LU2417539215.USD","LU2236285917.USD","MDCX","LU2456880835.USD","APC","LU2237443622.USD","LU0170899867.USD","LU1935042991.SGD","LU1935043023.USD","LU1935043536.SGD","LU0077335932.USD","LU1496350171.SGD","LU1935042488.USD","LU0882574139.USD","LU2083900584.USD","LU1066051811.HKD","LU1366192091.USD"],"gpt_icon":0},{"id":"2601889856","title":"Medicus Pharma Ltd. to Present at Biotech Showcase 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601889856","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601889856?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:30","pubTimestamp":1767616210,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. will present at the Biotech Showcase 2026 on Tuesday, January 13, 2026, in San Francisco. Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will deliver the company presentation as Medicus highlights multiple Phase 2 clinical catalysts and advances its partnering strategy. The presentation will be webcast live and available for replay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL9lNQYm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","LU2210149790.SGD","MDCX","BK4585","SG9999014021.USD","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2600566061","title":"ADVISORY-Dated alerts on Medicus Pharma withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2600566061","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600566061?lang=en_us&edition=fundamental","pubTime":"2026-01-02 23:56","pubTimestamp":1767369408,"startTime":"0","endTime":"0","summary":"ADVISORY-Dated alerts on Medicus Pharma withdrawnAlerts on Medicus Pharma MDCX.O entering into a sales agreement to sell $15.4 million worth shares were dated and have been withdrawn.For correct alert","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y202E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2600506923","title":"Medicus Pharma Ltd - Entered Into Sales Agreement With Maxim and Yorkville - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600506923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600506923?lang=en_us&edition=fundamental","pubTime":"2026-01-02 23:26","pubTimestamp":1767367612,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y202E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2600233069","title":"Medicus Pharma Ltd - May Offer and Sell Common Shares up to $15,349,674 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2600233069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600233069?lang=en_us&edition=fundamental","pubTime":"2026-01-02 23:26","pubTimestamp":1767367612,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nFWN3Y202E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2595671811","title":"Medicus Pharma Ltd - to Offer Shares up to $15.35 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595671811","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595671811?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:28","pubTimestamp":1767104904,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y002B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2595115718","title":"Medicus Pharma Ltd - on Dec 29, Entered Equity Distribution Agreement With Maxim Group & Yorkville Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595115718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595115718?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:28","pubTimestamp":1767104904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nFWN3Y002B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":74,"code":"91000000","status":"200"}]}}